Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Gains from Sales and Divestitures (2016)

Viridian Therapeutics, Inc.\DE (VRDN) has 3 years of Gains from Sales and Divestitures data on record, last reported at $52668.0 in Q4 2016.

  • For Q4 2016, Gains from Sales and Divestitures fell 88.53% year-over-year to $52668.0; the TTM value through Dec 2016 reached $52668.0, down 88.53%, while the annual FY2016 figure was $52668.0, 88.53% down from the prior year.
  • Gains from Sales and Divestitures reached $52668.0 in Q4 2016 per VRDN's latest filing, down from $154308.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $459208.0 in Q4 2015 and bottomed at $2352.0 in Q1 2016.
  • Average Gains from Sales and Divestitures over 3 years is $200390.3, with a median of $154308.0 recorded in 2016.
  • Peak YoY movement for Gains from Sales and Divestitures: surged 61.19% in 2015, then plummeted 98.15% in 2016.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $284893.0 in 2014, then soared by 61.19% to $459208.0 in 2015, then crashed by 88.53% to $52668.0 in 2016.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $52668.0 in Q4 2016, $154308.0 in Q3 2016, and $128956.0 in Q2 2016.